A. William Blackstock, Jr, MD | Authors

JAMES J HOWARD CLINIC PHARMACY

Articles

The ‘Watch-and-Wait’ Approach for Rectal Cancer: Are Outcomes Improved With More Limited T Stage and Routine Use of MRI for Staging?

October 15, 2013

We also propose that limiting the watch-and-wait strategy to patients with T1/T2N0 rectal cancer and using adequate T staging with MRI will result in improvements in local control and patient outcomes.

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

May 02, 2002

Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.

Treatment of Pancreatic Cancer: Current Limitations, Future Possibilities

March 01, 1996

In an attempt to improve the grave prognosis associated with the diagnosis of pancreatic cancer, researchers have explored a number of novel therapies. These include hormonal therapy, immunotherapy, radiopharmaceuticals, and novel chemotherapeutic agents.

Commentary (Blackstock/Tepper): Current Status of Radiation Sensitization by Fluoropyrimidines

August 01, 1995

The authors present a thorough review of the mechanisms and clinical effects of fluoropyrimidine radiation sensitization. As they discuss, abundant clinical data from multiple tumor sites show improved outcome when radiation is delivered in